The BRILLIANT Study

This study has been terminated.
(Sponsor decision)
Sponsor:
Information provided by (Responsible Party):
Vascular Solutions, Inc
ClinicalTrials.gov Identifier:
NCT00618514
First received: February 6, 2008
Last updated: March 20, 2015
Last verified: June 2013
  Purpose

This trial was designed as a prospective, multi-center, randomized clinical trial of the FDA-cleared Vari-Lase Bright Tip Fiber compared to commercially available standard bare-tip laser fiber (control) to demonstrate the safety and effectiveness of laser ablation for the treatment of varicose veins associated with reflux within the great saphenous vein (GSV) and to provide additional data concerning patient satisfaction. Within this evaluation, subject limbs were randomized to one of two (2) treatment groups utilizing a 1:1 randomization ratio. If a subject required treatment of only one limb, that limb was randomized to a treatment group. If a subject required treatment of two limbs, the first limb was randomly assigned treatment and the second limb was assigned the other treatment (the opposite treatment of the other limb). The data was analyzed by treated limb (versus treated subject).All study data were analyzed under the principles of intent-to-treat, in which data are analyzed according to the assigned randomized group regardless of the treatment actually delivered. Subjects were followed at one week, one month, and six months.


Condition Intervention
Varicose Veins
Device: Bright Tip Laser Fiber
Device: Bare Tip Laser Fiber

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Comparative Evaluation of the FDA-Cleared Bright Tip Laser Fiber Versus Commercially Available Bare Laser Fiber (the Control) in the Treatment of Reflux in the Greater Saphenous Vein (GSV) Using Endovenous Laser Therapy

Resource links provided by NLM:


Further study details as provided by Vascular Solutions, Inc:

Primary Outcome Measures:
  • Number of Limbs With a Continued Absence of Flow Within the Treated Vein Segment Over 6 Months. [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
    The absence of flow was evaluated in each treated limb and determined by ultrasound (duplex or Doppler) interrogation.

  • Number of Limbs With a Device-related Serious Adverse Event Reported Over 6 Months. [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
    Each treated limb was clinically evaluated for the presence of a device-related serious adverse event.


Secondary Outcome Measures:
  • Percent Change of Subject Symptoms in Treated Limb From Baseline to 6 Months Using Venous Clinical Severity Score (VCSS). [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
    VCSS is a physician's evaluation of 10 pre-determined clinical signs or attributes of venous disease (pain, varicose veins, venous edema, skin pigmentation, inflammation, induration, number of active ulcers, active ulcer duration, active ulcer diameter and compression therapy). Each attribute receives a score from 0-3 (0=absent and 3=severe). The best total overall score is 0 (all ten attributes are absent) and the worse overall score is 30 (all ten attributes are severe). Each treated limb was evaluated and scored at baseline and at 6 months.

  • Percent Change of Subject Symptoms in Treated Limb From Baseline to 6 Months Using Venous Disability Score (VDS). [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
    VDS is a physician's evaluation of a patient's ability to work an eight-hour day with or without a support device (i.e., compressive therapy, limb elevation). The patient is scored on a scale of 0-3 (0=asymptomatic and 3=unable to carry out usual activities (patients activities before the onset of disability due to venous disease) even with compression and/or limb elevation). The score represents the degree of disability caused by the venous disease with the best score being 0 and the worse score being 3. Each treated limb was evaluated and scored at baseline and at 6 months.

  • Percent Change of Subject Symptoms in Treated Limb From Post-procedure to 6 Months Using Patient Visual Analog Scale (VAS) Pain Scores. [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
    Each subject completed a questionnaire to rate his/her pain. The scale is from 0-10 (0=no pain and 10=worst pain imaginable). Each treated limb was scored by the patient post-procedure and at 6 months to determine the improvement after treatment at the 6-month time point.

  • Percentage of Subjects Reporting an Excellent Satisfaction Score at 6 Months. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Each subject completed a questionnaire to rate their satisfaction with the laser treatment. The score was reported as excellent, good, fair or poor. The best score of excellent was defined as "I am very satisfied with the laser treatment" and the worse score of poor was defined as "I am not satisfied with the laser treatment." Each treated limb was scored by the patient at 6 months to determine the percent satisfaction at the 6-month time point.

  • Number of Limbs With a Device-related Non-serious Adverse Event Reported Over 6 Months. [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]
    Each treated limb was clinically evaluated for the presence of a device-related non-serious adverse event.


Enrollment: 93
Study Start Date: June 2008
Study Completion Date: August 2009
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Bright Tip Laser Fiber - FDA-cleared study device
Device: Bright Tip Laser Fiber
Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
Other Name: Bright Tip Laser Fiber
Active Comparator: 2
Standard bare tip Laser Fiber - Any commercially available laser device (the control)
Device: Bare Tip Laser Fiber
Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
Other Name: Bare Tip Laser Fiber

Detailed Description:

This trial was designed as a prospective, multi-center, randomized clinical trial of the FDA-cleared Vari-Lase Bright Tip Fiber compared to commercially available standard bare-tip laser fiber (control) to demonstrate the safety and effectiveness of laser ablation for the treatment of varicose veins associated with reflux within the great saphenous vein (GSV) and to provide additional data concerning patient satisfaction. Subjects were pre-screened utilizing standard of care data (including documented evidence of reflux within the GSV) for the specified inclusion/exclusion criteria to ensure that they were eligible for treatment in the investigation. Prior to laser treatment and after signing an informed consent form, study eligibility assessments were completed including physical assessment of target limb(s), duplex ultrasound of GSV segment(s) targeted for treatment, symptom assessment, medical history, and digital photos of targeted limbs. Upon enrollment, targeted limbs were randomized at a 1:1 ratio to receive the Vari-lase Bright Tip Fiber or the control treatment. If the subject required treatment of two limbs, the first limb was randomized and the second limb was assigned the other treatment (the opposite treatment of the other limb). Immediately post procedure, subjects were assessed for adverse events and a physical assessment of the treated limb(s) was performed. Subjects were also asked to complete a subject pain and satisfaction questionnaire. Subjects were followed at one week, one month, and six months. Follow-up included a physical assessment of treated limb(s), symptom assessment, adverse event assessment, and completion of a subject pain and satisfaction questionnaire. Additionally, a duplex ultrasound assessment was conducted at one week and six months and digital photos were taken of the treated vein segment(s) at one week and one month. The data was analyzed by treated limb (versus treated subject). All study data were analyzed under the principles of intent-to-treat, in which data are analyzed according to the assigned randomized group regardless of the treatment actually delivered.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is 18 years of age or older
  2. Subjects with primary varicose veins resultant of GSV reflux documented on duplex ultrasound
  3. Subjects that will be undergoing endovenous laser ablation treatment of varicose veins
  4. Subjects treatment includes the Greater Saphenous Vein
  5. If bilateral, subject is willing and able to undergo treatment of both legs within two weeks.
  6. Subjects who are willing and able to comply with the requirements of the study protocol
  7. Subjects who are willing and able to provide informed consent

Exclusion Criteria:

  1. Subjects with severe peripheral vascular disease (PVD) as evidenced by an ankle-brachial index of < 0.5
  2. Subjects who are unable to ambulate at baseline
  3. Subjects with thrombosis in the vein segment(s) to be treated
  4. Subjects that have had prior vein treatment
  5. Subjects who are known or suspected to be pregnant or lactating
  6. Subjects that are concurrently participating in an investigational study that may confound the treatment or outcomes of the present study
  7. Subjects with an active or systemic infection
  8. Anatomic variants- duplication of the GSV, presence of incompetent accessory veins of the GSV
  9. Subjects who are scheduled to have a bilateral treatment, where one limb is to be enrolled in this study and the second limb that is not treated as part of this study, is treated within two months of the procedure for this study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00618514

Locations
United States, Alabama
Southeast Vein and Laser
Dothan, Alabama, United States, 36303
United States, Arizona
Morrision Vein Institute
Scottsdale, Arizona, United States, 85255
United States, Florida
HealthwoRx
Hollywood, Florida, United States, 33021
Mackay Center for Vein Treatment and Laser Therapy
Palm Harbor, Florida, United States, 34683
United States, North Carolina
Comprehensive Wound Care
Kinston, North Carolina, United States, 28501
United States, Pennsylvania
Pottstown Memorial Hospital
Pottstown, Pennsylvania, United States, 19464
United States, Virginia
The Vein Center of Virginia
Virginia Beach, Virginia, United States, 23452
Sponsors and Collaborators
Vascular Solutions, Inc
Investigators
Principal Investigator: Robert Worthington-Kirsch, MD Image Guided Surgery Associates
  More Information

No publications provided

Responsible Party: Vascular Solutions, Inc
ClinicalTrials.gov Identifier: NCT00618514     History of Changes
Other Study ID Numbers: 0407
Study First Received: February 6, 2008
Results First Received: January 26, 2010
Last Updated: March 20, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Vascular Solutions, Inc:
Varicose Veins
Laser Ablation
Laser Wire Fibers

Additional relevant MeSH terms:
Varicose Veins
Cardiovascular Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on April 19, 2015